Literature DB >> 2303836

The blood/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis.

P Phuapradit1, K Supmonchai, S Kaojarern, C Mokkhavesa.   

Abstract

Concentrations of pyrazinamide were measured in serum and cerebrospinal fluid (CSF) of 17 adult patients with tuberculous meningitis up to six months after starting treatment. Pyrazinamide penetrated excellently into the CSF and mean concentrations at various intervals up to six months of treatment were consistently above that required for inhibition of the growth of Mycobacterium tuberculosis. The blood/CSF partitioning of pyrazinamide does not change as the patients recover from the meningitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2303836      PMCID: PMC1014104          DOI: 10.1136/jnnp.53.1.81

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  10 in total

1.  Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis.

Authors:  G A Ellard; M J Humphries; M Gabriel; R Teoh
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-31

2.  Pyrazinamide in treatment of tuberculous meningitis.

Authors:  A Pauranik; M Behari; M C Maheshwari
Journal:  Arch Neurol       Date:  1986-10

3.  Treatment of tuberculous meningitis: role of short-course chemotherapy.

Authors:  P Phuapradit; A Vejjajiva
Journal:  Q J Med       Date:  1987-03

4.  Cerebrospinal fluid pyrazinamide concentrations in children with tuberculous meningitis.

Authors:  P R Donald; H Seifart
Journal:  Pediatr Infect Dis J       Date:  1988-07       Impact factor: 2.129

5.  Pyrazinamide and other drugs in tuberculous meningitis.

Authors:  R Forgan-Smith; G A Ellard; D Newton; D A Mitchison
Journal:  Lancet       Date:  1973-08-18       Impact factor: 79.321

6.  Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar.

Authors:  K D Stottmeier; R E Beam; G P Kubica
Journal:  Am Rev Respir Dis       Date:  1967-11

7.  Killing of macrophage-ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in combination.

Authors:  N A Carlone; G Acocella; A M Cuffini; M Forno-Pizzoglio
Journal:  Am Rev Respir Dis       Date:  1985-12

8.  Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

9.  Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids.

Authors:  P Gurumurthy; N G Nair; G R Sarma
Journal:  Indian J Med Res       Date:  1980-01       Impact factor: 2.375

10.  Hepatic toxicity during chemotherapy for severe tuberculosis meningitis.

Authors:  P R Donald; J F Schoeman; A O'Kennedy
Journal:  Am J Dis Child       Date:  1987-07
  10 in total
  7 in total

1.  The management of tuberculous meningitis.

Authors:  M Humphries
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

2.  Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study.

Authors:  Christopher Vinnard; Carla A Winston; E Paul Wileyto; Rob Roy Macgregor; Gregory P Bisson
Journal:  BMJ       Date:  2010-09-06

Review 3.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

Review 4.  Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.

Authors:  R Nau; F Sörgel; H W Prange
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

Review 5.  Central nervous system tuberculosis: pathogenesis and clinical aspects.

Authors:  R Bryan Rock; Michael Olin; Cristina A Baker; Thomas W Molitor; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 6.  Treatment of tuberculous infection and disease in children: the North American perspective.

Authors:  C D Stowe; R F Jacobs
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.930

Review 7.  Six months therapy for tuberculous meningitis.

Authors:  Sophie Jullien; Hannah Ryan; Manish Modi; Rohit Bhatia
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.